BioMarin Reports Full-Year 2025 Results, Details Amicus Acquisition, and ROCTAVIAN Withdrawal

summarizeSummary

BioMarin Pharmaceutical Inc. filed its 2025 annual report, detailing a major $4.8 billion acquisition of Amicus Therapeutics, the $285 million acquisition of Inozyme Pharma, and the voluntary withdrawal of its ROCTAVIAN gene therapy from the market, resulting in $240 million in restructuring charges. Full-year revenues increased, but net income and diluted EPS declined.

check_boxKey Events

• Strategic Acquisitions Detailed

  BioMarin entered into a definitive agreement in December 2025 to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction, expected to close in Q2 2026. This follows the July 2025 acquisition of Inozyme Pharma for $285 million, adding the late-stage enzyme replacement therapy BMN 401 to its pipeline. The Amicus acquisition will be financed through cash on hand and approximately $3.7 billion of non-convertible debt, including $850 million in 5.5% senior unsecured notes issued in February 2026.

• ROCTAVIAN Gene Therapy Withdrawn

  The company committed to voluntarily withdraw its ROCTAVIAN gene therapy from the market in December 2025 due to lower than previously anticipated commercial opportunities. This strategic decision resulted in approximately $240 million of restructuring charges in 2025, including an inventory write-off and impairment of long-lived assets.

• Full-Year 2025 Financial Performance

  Total revenues increased to $3.22 billion in 2025 from $2.85 billion in 2024. However, net income decreased to $348.9 million from $426.9 million, and diluted earnings per share fell to $1.80 from $2.21, primarily impacted by the ROCTAVIAN restructuring charges and a $221 million acquired In-Process Research and Development (IPR&D) expense from the Inozyme acquisition.

• Ongoing DOJ Subpoena Disclosure

  The company reiterated its disclosure of an ongoing U.S. Department of Justice (DOJ) subpoena, first received in 2023, requesting documents regarding sponsored testing programs related to VIMIZIM and NAGLAZYME. BioMarin is cooperating fully with the investigation.

auto_awesomeAnalysis

This annual report provides a comprehensive overview of BioMarin's strategic shifts and financial performance for 2025. The company is undergoing a significant portfolio transformation, marked by two key acquisitions aimed at expanding its rare disease therapies. However, this growth strategy is accompanied by the notable failure and withdrawal of its gene therapy, ROCTAVIAN, incurring substantial charges. While revenues grew, profitability declined due to these strategic adjustments and associated expenses. Investors should consider the long-term potential of the acquired assets against the immediate financial impact of the ROCTAVIAN write-off and increased debt load.